Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
News | May 30, 2020
From June 1st to June 7th 2020 is World Haemochromatosis Week.
Hemochromatosis is characterised by an excess of iron in blood. Causes for the disease are mostly hereditary and the illness can be diagnosed by genetic testing. Hemochromatosis is often overlooked because its symptoms are generally non-specific and can be confused with other illnesses.
The excess iron deposited in a variety of organs can however lead to irreversible tissue damage, particularly in the liver and pancreas, which leads to serious diseases such as cirrhosis, diabetes, arthritis or hypogonadism.
Early diagnosis of the disease is thus crucial.
The single tube PCR reagent kit Devyser HFE allows a fast and specific detection of mutations in the HFE gene.
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More